B2M
Beta-2-microglobulin
Protein Summary
Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation (PubMed:25356553). This gene encodes a serum protein found in association with the major histocompatibility complex (MHC) class I heavy chain on the surface of nearly all nucleated cells. The protein has a predominantly beta-pleated sheet structure that can form amyloid fibrils in some pathological conditions. The encoded antimicrobial protein displays antibacterial activity in amniotic fluid. A mutation in this gene has been shown to result in hypercatabolic hypoproteinemia.[provided by RefSeq, Aug 2014]
- ENST00000558401
- ENSP00000452780
- ENSG00000166710
- ENST00000559916
- ENSP00000453350
- ENST00000561424
- ENSP00000453191
- ENST00000617605
- ENSP00000481426
- ENSG00000273686
- ENST00000631573
- ENSP00000488548
- ENST00000631728
- ENSP00000488321
- ENST00000648006
- ENSP00000497910
- IMD43
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 1 | ||
disease perturbation | 1 | ||
virus perturbation | 1 | ||
kinase perturbation | 0.99 | ||
transcription factor perturbation | 0.94 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 8925.37 (req: < 5)
Gene RIFs: 313 (req: <= 3)
Antibodies: 2183 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 8925.37 (req: >= 5)
Gene RIFs: 313 (req: > 3)
Antibodies: 2183 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 39
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0